200185-91-7

Basic information

• Product Name: Ethyl 6-broMo-3-Methylbenzofuran-2-carboxylate
• Synonyms: Ethyl 6-broMo-3-Methylbenzofuran-2-carboxylate
• CAS NO: 200185-91-7
• Molecular Formula: C₁₂H₁₁BrO₃
• Molecular Weight: 283.11794
• Mol File: 200185-91-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 6-broMo-3-Methylbenzofuran-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 6-broMo-3-Methylbenzofuran-2-carboxylate(200185-91-7)
• EPA Substance Registry System: Ethyl 6-broMo-3-Methylbenzofuran-2-carboxylate(200185-91-7)

Safety Data

• Hazardous Substances Data: 200185-91-7(Hazardous Substances Data)

Upstream product

• 30186-18-6 4'-bromo-2'-hydroxyacetophenone 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 907945-33-9 ethyl 6-(4-chlorophenyl)-3-methyl-1-benzofuran-2-carboxylate 
• 907945-37-3 ethyl 6-(4-formylphenyl)-3-methyl-1-benzofuran-2-carboxylate 

Relevant articles and documents

HDAC inhibitor and preparation method and application thereof

The present invention discloses a compound represented by a formula I, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The invention further relates to a pharmaceutical composition containing the compound shown in the formula I and application of the compound in preparation of HDAC inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for treating cell proliferation diseases, autoimmune diseases, inflammation, neurodegenerative diseases or viral diseases.

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.